YM-440

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530134

CAS#: 163300-58-1

Description: YM-440 is an insulin sensitizer potentially for the treatment of type 2 diabetes. Through research, it has proven to be a novel hypoglycemic agent by suppressing hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker rats.


Price and Availability

Size
Price

Size
Price

Size
Price

YM-440 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 530134
Name: YM-440
CAS#: 163300-58-1
Chemical Formula: C22H20N4O8
Exact Mass: 468.13
Molecular Weight: 468.42
Elemental Analysis: C, 56.41; H, 4.30; N, 11.96; O, 27.32


Synonym: YM-440; YM440; YM 440

IUPAC/Chemical Name: (Z)-2,2'-(((but-2-ene-1,4-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(1,2,4-oxadiazolidine-3,5-dione)

InChi Key: LUACLLSCZRRTIH-UPHRSURJSA-N

InChi Code: InChI=1S/C22H20N4O8/c27-19-23-21(29)33-25(19)13-15-3-7-17(8-4-15)31-11-1-2-12-32-18-9-5-16(6-10-18)14-26-20(28)24-22(30)34-26/h1-10H,11-14H2,(H,23,27,29)(H,24,28,30)/b2-1-

SMILES Code: O=C(N1)N(CC2=CC=C(OC/C=C\COC3=CC=C(CN(C(N4)=O)OC4=O)C=C3)C=C2)OC1=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Nakano R, Kurosaki E, Shimaya A, Kajikawa S, Shibasaki M. YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction. Eur J Pharmacol. 2006 Nov 7;549(1-3):185-91. PubMed PMID: 16989806.

2: Nakano R, Kurosaki E, Shimaya A, Shibasaki M. The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats. J Pharmacol Sci. 2006 Aug;101(4):311-7. PubMed PMID: 16891767.

3: Kurosaki E, Nakano R, Momose K, Shimaya A, Suzuki T, Shibasaki M, Shikama H. Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker rats. Eur J Pharmacol. 2003 May 9;468(2):151-8. PubMed PMID: 12742522.

4: Kurosaki E, Nakano R, Shimaya A, Yoshida S, Ida M, Suzuki T, Shibasaki M, Shikama H. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation. Biochem Pharmacol. 2003 Mar 1;65(5):795-805. PubMed PMID: 12628477.

5: Yamanouchi T. [Chemical structures and pharmacological characteristics of novel non-thiazolidinedione insulin sensitizer (JTT-501, FK614)]. Nihon Rinsho. 2002 Sep;60 Suppl 9:573-7. Review. Japanese. PubMed PMID: 12387053.

6: Kurosaki E, Momose K, Nakano R, Shimaya A, Suzuki T, Shibasaki M, Shikama H. Hypoglycemic agent YM440 ameliorates the impaired hepatic glycogenesis after glucose loading by increasing glycogen synthase activity in obese Zucker rats. Jpn J Pharmacol. 2002 Jul;89(3):274-81. PubMed PMID: 12184733.

7: Shimaya A, Kurosaki E, Nakano R, Hirayama R, Shibasaki M, Shikama H. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism. 2000 Mar;49(3):411-7. PubMed PMID: 10726922.